Semi-mechanistic efficacy model for PARP + ATR inhibitors…

Semi-mechanistic efficacy model for PARP + ATR inhibitors—application to rucaparib and talazoparib in combination with gartisertib in breast cancer PDXs

By Claire C. Villette, Nathalie Dupuy, Frances A. Brightman, Astrid Zimmermann, Floriane Lignet, Frank T. Zenke, Nadia Terranova, Jayaprakasam Bolleddula, Samer El Bawab & Christophe Chassagnole